Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer’s disease

Fig. 2

Bexarotene treatment corrects short-term memory deficits, and cognitive improvements are maintained after removal in vivo. Novel object recognition behavioral assay is displayed as the relative discrimination index for wildtype (WT)-vehicle and APP/PS1 (Tg)-vehicle or bexarotene-treated mice for each treatment group. The relative discrimination index (see the “Methods” section) was determined as the ratio between the difference in time spent investigating novel and familiar objects to the total time investigating both objects. Relative discrimination indexes of 0 represent lack of discrimination between novel and familiar object while values greater than 0 represent recognition of the novel object. **p < 0.01 and ***p < 0.001 with respect to WT vehicle and #p < 0.05 and ##p < 0.01 with respect to Tg vehicle, one-way ANOVA with Tukey post hoc test for multiple corrections. Fourteen days on (n = 10, 4, 6) and 14 days on + 14 days off (n = 14, 9, 10) for WT vehicle, Tg vehicle, Tg bexarotene, respectively. The 14 days on group contains mice that were subsequently tested in the 14 days on + 14 days off group

Back to article page